Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Chang, Alex Y ^a,b   Wang, Miao ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Johns Hopkins Singapore   (Singapore)

Author keywords

Biomarker; Dasatinib; Hepatocellular carcinoma; Mechanism of inhibition; Src kinase

Indexed keywords

DASATINIB; FOCAL ADHESION KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 42; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL MOTION; DRUG EFFECTS; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; LIVER NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SIGNAL TRANSDUCTION; THIAZOLES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84878263307     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-267     Document Type: Article

References (36)

1. Farazi PA, DePinho RA. The genetic and environmental basis of hepatocellular carcinoma. Discov Med 2006, 6(35):182-186.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362(9399):1907-1917. 10.1016/S0140-6736(03)14964-1, 14667750.
3. Kawano Y, Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, Shibata K, Ohta M, Kitano S. Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol 2009, 35(2):174-179. 10.1016/j.ejso.2008.01.027, 18325724.
4. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000, 32(6):1224-1229. 10.1053/jhep.2000.20456, 11093728.
5. Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 2009, 100(1):1-8. 10.1111/j.1349-7006.2008.01006.x, 19038007.
6. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997, 13:513-609. 10.1146/annurev.cellbio.13.1.513, 9442882.
7. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006, 12(5):1398-1401. 10.1158/1078-0432.CCR-05-2692, 16533761.
8. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004, 4(6):470-480. 10.1038/nrc1366, 15170449.
9. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R, Muro-Cacho CA. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 2006, 12(1):20-28. 10.1158/1078-0432.CCR-04-1749, 16397019.
10. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004, 4(2):97-105. 10.1038/nrc1275, 14964307.
11. Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell 2004, 6(3):209-214. 10.1016/j.ccr.2004.09.001, 15380511.
12. Lau GM, Lau GM, Yu GL, Gelman IH, Gutowski A, Hangauer D, Fang JW. Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Dig Dis Sci 2009, 54(7):1465-1474. 10.1007/s10620-008-0519-0, 18979199.
13. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354(24):2531-2541. 10.1056/NEJMoa055229, 16775234.
14. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, Gollerkeri A, Coutre S. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007, 110(7):2309-2315. 10.1182/blood-2007-02-073528, 17496201.
15. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005, 65(20):9185-9189. 10.1158/0008-5472.CAN-05-1731, 16230377.
16. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005, 11(19 Pt 1):6924-6932.
17. Frame MC. Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 2004, 117(Pt 7):989-998.
18. Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar AP. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett 2009, 283(2):143-151. 10.1016/j.canlet.2009.03.035, 19398150.
19. Luo FR, Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML, Smykla R, Fager K, Wild R, Palme H, Galbraith S, Blackwood-Chirchir A, Lee FY. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol 2008, 62(6):1065-1074. 10.1007/s00280-008-0699-5, 18301894.
20. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, Lee F, Shaw P, Clark E. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007, 67(5):2226-2238. 10.1158/0008-5472.CAN-06-3633, 17332353.
21. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006, 66(11):5542-5548. 10.1158/0008-5472.CAN-05-4620, 16740687.
22. Chang AY, Wang M. In vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma. Anticancer Drugs 2013, 24(3):251-259. 10.1097/CAD.0b013e32835ba289, 23187461.
23. Leung EL, Tam IY, Tin VP, Chua DT, Sihoe AD, Cheng LC, Ho JC, Chung LP, Wong MP. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy. Mol Cancer Res 2009, 7(6):923-932. 10.1158/1541-7786.MCR-09-0003, 19491201.
24. Chung BM, Dimri M, George M, Reddi AL, Chen G, Band V, Band H. The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene 2009, 28(16):1821-1832. 10.1038/onc.2009.31, 2752420, 19305428.
25. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2000, 2(3):203-210. 10.1186/bcr55, 138776, 11250711.
26. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(8):1387-1394. 10.1200/JCO.2009.25.4029, 3040065, 20142592.
27. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(30):4609-4615. 10.1200/JCO.2010.30.5474, 2974341, 20855820.
28. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci 2003, 116(Pt 8):1409-1416.
29. Sánchez-Bailón MP, Calcabrini A, Gómez-Domínguez D, Morte B, Martín-Forero E, Gómez-López G, Molinari A, Wagner KU, Martín-Pérez J. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells. Cell Signal 2012, 24(6):1276-1286. 10.1016/j.cellsig.2012.02.011, 22570868.
30. González L, Agulló-Ortuño MT, García-Martínez JM, Calcabrini A, Gamallo C, Palacios J, Aranda A, Martín-Pérez J. Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem 2006, 281(30):20851-20864. 10.1074/jbc.M601570200, 16728403.
31. Bai XM, Zhang W, Liu NB, Jiang H, Lou KX, Peng T, Ma J, Zhang L, Zhang H, Leng J. Focal adhesion kinase: important to prostaglandin E2-mediated adhesion, igrationand invasion in hepatocellular carcinoma cells. Oncol Rep 2009, 1(1):129-136.
32. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res 2009, 69(5):1958-1965. 10.1158/0008-5472.CAN-08-2944, 2929826, 19223541.
33. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009, 69(9):3842-3849. 10.1158/0008-5472.CAN-08-2246, 2709758, 19383922.
34. Ceppi P, Papotti M, Monica V, Iacono ML, Saviozzi S, Pautasso M, Novello S, Mussino S, Bracco E, Volante M, Scagliotti GV. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Mol Cancer Ther 2009, 8(11):3066-3074. 10.1158/1535-7163.MCT-09-0151, 19861409.
35. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, Haura EB. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 2010, 6(4):291-299. 10.1038/nchembio.332, 2842457, 20190765.
36. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M, Li D, Ullrich R, Koker M, Fischer F, Shimamura T, Rauh D, Mermel C, Fischer S, Stuckrath I, Heynck S, Beroukhim R, Lin W, Winckler W, Shah K, LaFramboise T, Moriarty WF, Hanna M, Tolosi L, Rahnenfuhrer J, Verhaak R, Chiang D, Getz G, Hellmich M, Wolf J. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009, 119(6):1727-1740. 10.1172/JCI37127, 2689116, 19451690.